Collection of biological samples from patients with rare neurological diseases
Prospective Collection of Biological Samples From Patients With Rare Neurological Diseases
University Hospital, Toulouse · NCT04698421
This study is trying to collect biological samples from people with rare neurological diseases to see if they can find new markers that help diagnose and treat these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 6 Years to 99 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse (other) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT04698421 on ClinicalTrials.gov |
What this trial studies
This project aims to enhance the collection of biological samples from patients suffering from rare neurological disorders with known or suspected autoimmune origins. By gathering these samples, the study seeks to identify new biomarkers that can aid in the diagnosis and treatment of these conditions. The focus is on disorders such as autoimmune encephalitis and paraneoplastic neurological syndromes, where the immune system plays a critical role. The collected samples will be made available to the medical and scientific communities to foster the development of new therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates include patients of all ages with neurological disorders that have known or probable autoimmune involvement.
Not a fit: Patients with neurological damage that is not autoimmune in nature or those with known anemia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and prognostic tools for patients with rare neurological diseases.
How similar studies have performed: While the approach of collecting biological samples for autoimmune neurological disorders is established, the specific focus on rare conditions may present novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * all patients with neurological disorders, with known or probable autoimmune involvement. This includes adults and children and peripheral and/or central nervous system symptoms. * Social coverage up to date. Exclusion Criteria: * Patients with neurological damage from which the autoimmune character can be excluded. * Known anemia and hemoglobin \<10 g / dl * Patients under protective supervision (guardianship, curators) * Pregnant or breastfeeding woman
Where this trial is running
Toulouse
- Purpan University Hospital — Toulouse, France (RECRUITING)
Study contacts
- Principal investigator: Chloé Bost, PharmD, PhD — University Hospital, Toulouse
- Study coordinator: Chloé Bost, PharmD, PhD
- Email: bost.c@chu-toulouse.fr
- Phone: 5 61 77 61 44
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Nervous System Diseases, autoimmune encephalitis, paraneoplastic neurological syndrome, myasthenia, paraneoplastic cerebellar degeneration, rare neuropathologies with known/suspected autoimmune origin